Advancing clinical development for neuronopathic Hunter syndrome through a quantitatively‐driven rev...
Advancing clinical development for neuronopathic Hunter syndrome through a quantitatively‐driven reverse translation framework
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
A quantitatively‐driven evaluation of existing clinical data and associated knowledge to accelerate drug discovery and development is a highly valuable approach across therapeutic areas, but remains underutilized. This is especially the case for rare diseases for which development is particularly challenging. The current work outlines an organizati...
Alternative Titles
Full title
Advancing clinical development for neuronopathic Hunter syndrome through a quantitatively‐driven reverse translation framework
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_d0d9a9afbe2c4a97808826c10d992575
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d0d9a9afbe2c4a97808826c10d992575
Other Identifiers
ISSN
1752-8054,1752-8062
E-ISSN
1752-8062
DOI
10.1111/cts.13776
